Diagnosis, Testing, and Treatment of NTRK Fusion Cancers in 2026
For those of us managing NTRK fusion cancers, the shift from treating a lung or…
New Generic Oncology Medicines from Bangladesh: The 2026 Export Guide for Repotrex, Fruquin, and Quizar
Accessing the latest targeted cancer therapies is one of the greatest challenges in modern healthcare.…
Comparative Pharmacopeia: Olanib 150 mg and Olarigen 150 mg
Product Profile: Olanib 150 mg (Everest Pharmaceuticals Ltd.) Olanib 150 mg serves as a cornerstone…
The Patient Care Continuum: Managing Life on Generic Olaparib
Managing Hematological Toxicity: Anemia and Neutropenia Hematological adverse events are among the most common reasons…
The Therapeutic Paradigm of PARP Inhibition and the Economics of Access in Oncology
The Evolution of Targeted Oncology and the Generic Imperative The trajectory of modern oncology has…
Differentiation Syndrome: What AML Patients on Gilteritinib Need to Watch For
Targeted therapy is different from chemotherapy. Instead of killing cells instantly, Gilteritinib forces leukemia cells…
Generic Gilteritinib vs. XOSPATA: Is There a Difference in Quality?
For many AML patients, the cost of maintenance therapy is the biggest barrier to health.…
FLT3-Mutated Acute Myeloid Leukemia (AML): A 2025 Patient’s Guide to Targeted Therapy
Receiving a diagnosis of Acute Myeloid Leukemia (AML) is overwhelming. But hearing that your AML…
Does Mold Cause Lung Cancer?
Mold is directly not responsible for lung cancer but it may be the potential cause…
Anaplastic Thyroid Cancer and Lenvatinib
Anaplastic thyroid cancer (ATC) is a rare, aggressive form of thyroid cancer that constitutes about 1-2% of all thyroid cancer cases.
